2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA).

Open Access Oral presentation 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) N Ruperto*1, P Quartier2, N Wulffraat3, P Woo4, A Loy1, R Mouy2, B BaderMeunier2, B Prakken3, E Noseda5, C Rordorf5 and Martini for the Paediatric Rheumatology International Trials Organisation (PRINTO) A1